Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.50 |
| ▸ | KDR | P35968 | 1/20 | 0.50 |
| ▸ | RAF1 | P04049 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23051387 | 0.91 | MEN1 (0.55) | MEN1KMT2ASMN1; SMN2LMNAMAPT | |
| SCHEMBL29625932 | 0.91 | MEN1 (0.55) | MEN1KMT2ASMN1; SMN2LMNAMAPT | |
| SCHEMBL6565686 | 0.88 | KMT2A (0.55) | MEN1KMT2ASMN1; SMN2LMNAMAPT | |
| SCHEMBL21295536 | 0.83 | KDR (0.61) | MEN1KMT2ALMNATP53TSHR | |
| SCHEMBL6566525 | 0.83 | SMN1; SMN2 (0.52) | MEN1KMT2ASMN1; SMN2LMNATP53 | |
| SCHEMBL21295431 | 0.82 | STK39 (0.58) | MEN1KMT2ASMN1; SMN2LMNATP53 | |
| SCHEMBL6568164 | 0.81 | MEN1 (0.50) | MEN1KMT2ASMN1; SMN2LMNATP53 | |
| SCHEMBL6566692 | 0.81 | MEN1 (0.61) | MEN1KMT2ASMN1; SMN2LMNAHIF1A | |
| SCHEMBL6567903 | 0.81 | MEN1 (0.61) | MEN1KMT2ASMN1; SMN2LMNAMAPT | |
| SCHEMBL23051388 | 0.81 | NPSR1 (0.49) | MEN1KMT2ASMN1; SMN2LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250214948-A1 | TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS | AlzeCure Pharma AB (SE) | 2025-07-03 | — | — | US | disclosed |
| CN-112513032-B | 4-Substituted phenyl-1, 3, 5-triazine derivatives as modulators of TRK receptors | 阿泽克制药公司 | 2024-07-02 | — | — | CN | disclosed |
| US-11840524-B2 | 4-substituted phenyl-1,3,5-triazine derivatives as modulators of TrK receptors | AlzeCure Pharma AB (SE) | 2023-12-12 | — | — | US | disclosed |
| US-11840524-B2 | 4-substituted phenyl-1,3,5-triazine derivatives as modulators of TrK receptors | AlzeCure Pharma AB (SE) | 2023-12-12 | — | — | US | disclosed |
| US-11840524-B2 | 4-substituted phenyl-1,3,5-triazine derivatives as modulators of TrK receptors | AlzeCure Pharma AB (SE) | 2023-12-12 | — | — | US | disclosed |
| EP-3759088-B1 | TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS | AlzeCure Pharma AB (SE) | 2023-01-25 | — | — | EP | disclosed |
| EP-3814335-B1 | 4-SUBSTITUTED PHENYL-1,3,5-TRIAZINE DERIVATIVES AS MODULATORS OF TRK RECEPTORS | AlzeCure Pharma AB (SE) | 2022-11-09 | — | — | EP | disclosed |
| US-20220306589-A1 | TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS | AlzeCure Pharma AB (SE) | 2022-09-29 | — | — | US | disclosed |
| US-11352332-B2 | Triazine derivatives for treating diseases relating to neurotrophins | AlzeCure Pharma AB (SE) | 2022-06-07 | — | — | US | disclosed |
| US-20210371402-A1 | 4-SUBSTITUTED PHENYL-1,3,5-TRIAZINE DERIVATIVES AS MODULATORS OF TRK RECEPTORS | AlzeCure Pharma AB (SE) | 2021-12-02 | — | — | US | disclosed |
| US-20210371402-A1 | 4-SUBSTITUTED PHENYL-1,3,5-TRIAZINE DERIVATIVES AS MODULATORS OF TRK RECEPTORS | AlzeCure Pharma AB (SE) | 2021-12-02 | — | — | US | disclosed |
| EP-3814335-A1 | 4-SUBSTITUTED PHENYL-1,3,5-TRIAZINE DERIVATIVES AS MODULATORS OF TRK RECEPTORS | Alzecure Pharma AB (SE) | 2021-05-05 | — | — | EP | disclosed |
| CN-112513032-A | 4-substituted phenyl-1, 3, 5-triazine derivatives as modulators of TRK receptors | 阿泽克制药公司 | 2021-03-16 | — | — | CN | disclosed |
| EP-3759088-A1 | TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS | Alzecure Pharma AB (SE) | 2021-01-06 | — | — | EP | disclosed |
| US-20200399230-A1 | TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS | AlzeCure Pharma AB (SE) | 2020-12-24 | — | — | US | disclosed |
| WO-2019162702-A1 | TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS | AlzeCure Pharma AB (SE) | 2019-08-29 | — | — | WO | disclosed |
| US-20040259912-A1 | Benzine derivatives, process for preparing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-12-23 | — | — | US | disclosed |
| EP-1437344-A1 | BENZENE DERIVATIVES,PROCESS FOR PREPARING THE SAME AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2004-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220306589-A1 | TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS | NTRK2, BDNF, NGF | MEN1 2076/4885KMT2A 3034/4885SMN1; SMN2 649/4885 |
| US-11840524-B2 | 4-substituted phenyl-1,3,5-triazine derivatives as modulators of TrK receptors | NTRK2, NTRK3, BDNF | MEN1 4138/4885KMT2A 2828/4885SMN1; SMN2 1548/4885 |
| US-20250214948-A1 | TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS | NTRK2, BDNF, NGF | MEN1 2076/4885KMT2A 3034/4885SMN1; SMN2 649/4885 |
| US-11352332-B2 | Triazine derivatives for treating diseases relating to neurotrophins | NTRK2, BDNF, NGF | MEN1 1771/4885KMT2A 3022/4885SMN1; SMN2 619/4885 |
| US-20210371402-A1 | 4-SUBSTITUTED PHENYL-1,3,5-TRIAZINE DERIVATIVES AS MODULATORS OF TRK RECEPTORS | NTRK2, NTRK3, BDNF | MEN1 4138/4885KMT2A 2828/4885SMN1; SMN2 1548/4885 |
| US-20040259912-A1 | Benzine derivatives, process for preparing the same and use thereof | HRH4, HRH2, HRH1 | MEN1 4143/4885KMT2A 3137/4885SMN1; SMN2 2126/4885 |
| US-20200399230-A1 | TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS | NTRK2, BDNF, NGF | MEN1 1771/4885KMT2A 3022/4885SMN1; SMN2 619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.